How to Get Wegovy in Washington

Who Qualifies for Wegovy in Washington

The FDA approved semaglutide 2.4 mg (Wegovy) in June 2021 for chronic weight management in adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia 1. Washington state follows these same federal eligibility criteria. No state-specific restrictions narrow or expand the FDA label.

BMI and Comorbidity Documentation

Your prescriber will calculate your BMI from a measured height and weight. If your BMI falls between 27 and 29.9, you will need documentation of at least one weight-related condition. The Endocrine Society's 2024 clinical practice guideline recommends pharmacotherapy for patients with obesity who have not achieved target weight loss through lifestyle modification alone [2]. A recent visit note, lab panel, or problem list entry showing hypertension, obstructive sleep apnea, or type 2 diabetes typically satisfies this requirement.

Adolescent Eligibility

The FDA expanded Wegovy's label in December 2022 to include adolescents aged 12 and older with an initial BMI at or above the 95th percentile for age and sex 3. The STEP TEENS trial (N=201) demonstrated that semaglutide 2.4 mg produced a 16.1% reduction in BMI versus a 0.6% increase with placebo over 68 weeks [3]. Washington providers can prescribe Wegovy off this expanded label to qualifying adolescents.

Telehealth Prescribing in Washington

Washington law permits licensed prescribers to evaluate and prescribe controlled and non-controlled medications via telehealth, including GLP-1 receptor agonists like Wegovy. The state does not require an initial in-person visit before a telehealth prescription for semaglutide 4.

How a Telehealth Visit Works

A typical telehealth consultation for Wegovy in Washington involves a synchronous video or audio visit with a physician (MD/DO), nurse practitioner (NP), or physician assistant (PA). Washington grants NPs full practice authority, meaning they can prescribe Wegovy independently without physician oversight 5. During the visit, the provider reviews your medical history, current medications, and weight-related comorbidities. You may be asked to self-report your height and weight, or to provide measurements taken at a local pharmacy or urgent care clinic.

Choosing a Telehealth Provider

When evaluating telehealth platforms, verify three things: that the provider is licensed in Washington state, that they perform a medical evaluation (not just a questionnaire), and that they offer follow-up visits for dose titration. The American Telemedicine Association recommends that obesity telehealth programs include structured follow-up at each dose escalation step 6. Wegovy requires four dose increases over 16 to 20 weeks, moving from 0.25 mg to 0.5 mg to 1.0 mg to 1.7 mg and finally to the maintenance dose of 2.4 mg 1.

Required Labs Before Starting Wegovy

No single lab panel is universally mandated before starting semaglutide 2.4 mg, but clinical guidelines and insurer prior authorization forms frequently require baseline metabolic data.

Standard Pre-Prescription Lab Work

Most Washington prescribers order these baseline labs before initiating Wegovy:

• Fasting blood glucose and HbA1c to screen for or monitor type 2 diabetes. The American Diabetes Association recommends HbA1c testing in all adults with a BMI ≥25 who have additional risk factors 7.
• Lipid panel (total cholesterol, LDL, HDL, triglycerides). The STEP-1 trial reported that semaglutide 2.4 mg reduced triglycerides by 17.4% and C-reactive protein by 34.2% versus placebo at 68 weeks 8.
• Comprehensive metabolic panel to assess kidney and liver function, particularly in patients with type 2 diabetes or those on metformin.
• Thyroid function tests (TSH at minimum). The Wegovy label carries a boxed warning about thyroid C-cell tumors observed in rodent studies, though human relevance remains unclear 1. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use semaglutide [1].

Ongoing Monitoring

The Obesity Medicine Association recommends reassessing weight, blood pressure, and metabolic markers every 3 to 6 months while on GLP-1 therapy 9. This schedule typically aligns with refill authorization windows set by Washington insurers.

Washington Medicaid Coverage for Wegovy

Washington Apple Health (Medicaid) covers Wegovy for chronic weight management with prior authorization. This makes Washington one of a growing number of states where Medicaid beneficiaries can access GLP-1 medications for obesity, not just diabetes 10.

Prior Authorization Requirements

Washington Medicaid prior authorization for Wegovy typically requires:

1. Documented BMI of 30 or greater (or ≥27 with a comorbidity) recorded within the past 6 months.
2. Evidence of lifestyle modification such as a nutrition counseling referral or documented participation in a structured diet and exercise program.
3. Clinical notes from the prescribing provider confirming the diagnosis of obesity and the rationale for pharmacotherapy.
4. Failure of or contraindication to lower-cost alternatives (some plans require trial of generic orlistat or phentermine first, though this varies by managed care organization).

A systematic review of GLP-1 access barriers found that prior authorization requirements delay treatment initiation by an average of 2 to 4 weeks 11. Washington's Health Care Authority has moved to reduce administrative burden for chronic disease medications, but the PA process for Wegovy remains active.

Commercial Insurance in Washington

Most major commercial insurers operating in Washington (Premera, Regence, Molina, Kaiser Permanente Northwest) cover Wegovy with prior authorization for members whose plans include anti-obesity medication benefits. Coverage varies significantly by plan tier. A 2023 analysis of employer-sponsored plans found that only 40% of commercial plans covered at least one anti-obesity medication 12. Check your specific formulary or call the number on your insurance card.

Filling Your Prescription: Pharmacy Options in Washington

Once you have a valid prescription and insurance authorization (if applicable), you can fill Wegovy at retail pharmacies, specialty pharmacies, or through mail-order services operating in Washington.

Retail and Specialty Pharmacies

Large chains like CVS, Walgreens, and Walmart pharmacies across Washington stock Wegovy, though availability can fluctuate. Novo Nordisk has intermittently implemented supply constraints on lower-dose starter pens to prioritize patients already titrating up 13. The FDA's drug shortage database tracks current Wegovy supply status in real time. Before driving to a pharmacy, call ahead to confirm that your prescribed dose is in stock.

503A Compounding Pharmacies

Washington licenses 503A compounding pharmacies that can prepare semaglutide formulations for individual patients with valid prescriptions. This route is sometimes used when brand-name Wegovy is unavailable or when patients lack insurance coverage for the branded product. The FDA has stated that compounded drugs are not FDA-approved and do not undergo the same safety and efficacy review as commercially manufactured products 14. The Washington State Board of Pharmacy regulates 503A facilities within the state.

Mail-Order and Specialty Delivery

Several Washington-licensed mail-order pharmacies deliver Wegovy directly to patients. Semaglutide requires cold-chain shipping (36°F to 46°F / 2°C to 8°C) until first use, so confirm that the pharmacy ships with validated cold packs 1. After first use, the Wegovy pen can be stored at room temperature (up to 86°F / 30°C) for 28 days.

Cost and Savings Programs

Wegovy's wholesale acquisition cost is approximately $1,349 per month (one 2.4 mg pen per week). For patients with commercial insurance, Novo Nordisk offers a savings card that may reduce out-of-pocket costs to as low as $0 for eligible patients for up to 13 fills, depending on plan design. Patients on government insurance (Medicaid, Medicare, Tricare) are not eligible for manufacturer savings cards.

Reducing Out-of-Pocket Costs

A cost-effectiveness analysis published in JAMA found that semaglutide 2.4 mg met conventional willingness-to-pay thresholds only when the price dropped below approximately $7,500 per year 15. Several strategies may lower your costs:

• Manufacturer savings card: available at Novo Nordisk's patient assistance website for commercially insured patients.
• Patient assistance programs: Novo Nordisk's PAP provides free medication to qualifying uninsured patients with household income below 400% of the federal poverty level.
• Step therapy optimization: some Washington insurers waive step therapy if the prescriber documents clinical contraindications to phentermine or orlistat.

Dose Titration and Timeline

Wegovy follows a fixed 16- to 20-week dose escalation schedule to reduce gastrointestinal side effects 1.

The Titration Schedule

| Weeks | Weekly Dose | Purpose | |-------|------------|---------| | 1 to 4 | 0.25 mg | Initiation | | 5 to 8 | 0.5 mg | Escalation | | 9 to 12 | 1.0 mg | Escalation | | 13 to 16 | 1.7 mg | Escalation | | 17+ | 2.4 mg | Maintenance |

What to Expect During Titration

In STEP-1 (N=1,961), the most common adverse events with semaglutide 2.4 mg were nausea (44.2%), diarrhea (31.5%), vomiting (24.8%), and constipation (24.2%) 8. Most gastrointestinal symptoms were mild to moderate and peaked during dose escalation weeks 1 through 8. The slow titration schedule is designed to minimize these effects. If side effects are intolerable at a given dose, your prescriber may extend that dose level for an additional 4 weeks before advancing.

Weight Loss Trajectory

Weight loss with Wegovy is not immediate. STEP-1 participants lost an average of 5.3% of body weight by week 12, 10.6% by week 28, and 14.9% by week 68 8. The STEP-4 trial demonstrated that discontinuing semaglutide after 20 weeks of treatment led to regain of approximately two-thirds of lost weight over the subsequent 48 weeks, supporting long-term continuation for sustained benefit 16.

Cardiovascular Benefits: The SELECT Trial

The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events (MACE) by 20% compared to placebo in adults with overweight or obesity and established cardiovascular disease, but without diabetes 17. This finding led the FDA to approve a cardiovascular risk reduction indication for Wegovy in March 2024.

Why SELECT Matters for Washington Patients

Heart disease is the leading cause of death in Washington state, according to CDC data [18]. The SELECT result means Washington prescribers now have a second clinical rationale for prescribing Wegovy: cardiovascular risk reduction in patients with established atherosclerotic cardiovascular disease and a BMI ≥27. Some insurers that previously denied coverage for "weight loss" may approve it under the cardiovascular indication.

Dr. A. Michael Lincoff, principal investigator of the SELECT trial, stated: "These findings establish that treatment with semaglutide to reduce body weight can independently lower cardiovascular risk regardless of baseline diabetes status" 17.

Who Can Prescribe Wegovy in Washington

Three types of licensed providers can prescribe Wegovy in Washington state:

Physicians, NPs, and PAs

• Physicians (MD/DO): Full prescribing authority. Any specialty can prescribe Wegovy; you do not need to see an endocrinologist or obesity medicine specialist.
• Nurse Practitioners (NP): Washington grants NPs full practice authority under RCW 18.79, meaning they can prescribe independently without a collaborative agreement with a physician 5.
• Physician Assistants (PA): PAs in Washington prescribe under a collaborative agreement with a physician, though the supervising physician does not need to be physically present.

A position statement from the American Association of Clinical Endocrinology (AACE) supports prescribing of anti-obesity medications by any qualified provider who performs appropriate screening and follow-up 19.

Finding a Provider

The American Board of Obesity Medicine maintains a searchable directory of board-certified obesity medicine specialists. In Washington, these providers are concentrated in the Seattle-Tacoma metro area, Spokane, and the Tri-Cities. For rural Washington residents, telehealth is often the most practical route to a qualified prescriber.

Transferring a Prescription to Washington

If you already have an active Wegovy prescription from another state, a Washington-licensed pharmacist can accept an electronic or verbal transfer from the dispensing pharmacy in your previous state. You do not need a new prescription from a Washington provider, though your existing prescriber must be willing to continue managing your care across state lines. If your prescriber cannot practice across state lines, you will need to establish care with a new Washington-licensed provider who can review your records and continue the prescription.

The STEP-5 trial (N=304) showed that patients who continued semaglutide 2.4 mg for 104 weeks maintained a 15.2% mean weight loss, reinforcing the importance of uninterrupted therapy during transitions 20.